A2 Biotherapeutics, an Agoura Hills, CA-based clinical-stage cell remedy firm creating logic-gated cell therapies to selectively goal tumor cells and shield regular cells, raised $80M in Sequence C funding.
Backers included The Column Group and Samsara BioCapital.
The corporate intends to make use of the funds for 3 scientific growth applications and development of its pipeline of CAR-T cell therapies primarily based on its proprietary Tmod™ platform expertise.
Led by Jim Robinson, chief govt officer, A2 Bio has offered a precision-targeting mobile system, the Tmod™ platform, that includes two receptors, an activator and a blocker, to purpose the armaments of immune cells straight at tumors to distinguish tumors from regular tissues. The activator acknowledges antigens on tumor cells that set off their destruction, whereas the blocker acknowledges antigens on regular cells that shield them. This new blocker expertise permits exact, personalised and efficient T cell concentrating on.
The corporate is presently conducting two seamless part 1/2 scientific research: EVEREST-1 learning A2B530 for pancreatic, lung and colorectal cancers by concentrating on carcinoembryonic antigen (CEA); and EVEREST-2 learning A2B694 for pancreatic, ovarian, lung, colorectal and mesothelioma cancers by concentrating on mesothelin (MSLN).
FinSMEs
09/01/2025
